Literature DB >> 8382345

Two nuclear signalling pathways for vitamin D.

C Carlberg1, I Bendik, A Wyss, E Meier, L J Sturzenbecker, J F Grippo, W Hunziker.   

Abstract

The dihydroxylated form of vitamin D3 (1,25-dihydroxy-D3)mediates a biological response by binding to intracellular receptors which belong to the steroid receptor superfamily. These receptors act as ligand-dependent transcription factors that bind to specific DNA sequences (reviewed in refs 6-9). We have identified two classes of vitamin D response elements that are activated either by the vitamin D receptor (VDR) alone or by heterodimers of VDR and the retinoid-X receptor-alpha (RXR-alpha). The motif GGGTGA arranged as a direct repeat with a spacing of six nucleotides or as a palindrome without spacing, or as an inverted palindrome with a 12-nucleotide spacing, confers vitamin D inducibility mediated by VDR alone. A second class of response elements, composed of directly repeated pairs of motifs (GGTCCA, AGGTCA, or GGGTGA) spaced by three nucleotides, is synergistically activated by RXR and VDR, but only in the presence of both ligands. Thus, the RXR ligand and the nature of the response element determine whether a nuclear receptor is co-regulated by RXR.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8382345     DOI: 10.1038/361657a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  107 in total

1.  Large-scale expression and purification of the human vitamin D receptor and its ligand-binding domain for structural studies.

Authors:  K Juntunen; N Rochel; D Moras; P Vihko
Journal:  Biochem J       Date:  1999-12-01       Impact factor: 3.857

2.  Structure of a thyroid hormone receptor DNA-binding domain homodimer bound to an inverted palindrome DNA response element.

Authors:  Yi Chen; Matthew A Young
Journal:  Mol Endocrinol       Date:  2010-07-07

3.  Regulation of VDR Expression in Apc-Mutant Mice, Human Colon Cancers and Adenomas.

Authors:  Charles Giardina; Masako Nakanishi; Awaad Khan; Anton Kuratnik; Wanli Xu; Bruce Brenner; Daniel W Rosenberg
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

4.  Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells.

Authors:  Yong Xu; Fang Fang; Daret K St Clair; Sajni Josson; Pradoldej Sompol; Ivan Spasojevic; William H St Clair
Journal:  Mol Cancer Ther       Date:  2007-06-29       Impact factor: 6.261

Review 5.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

6.  Identification of a vitamin D responsive element in the promoter of the rat cytochrome P450(24) gene.

Authors:  C N Hahn; D M Kerry; J L Omdahl; B K May
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

7.  Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins.

Authors:  S R Patel; H Q Ke; R Vanholder; R J Koenig; C H Hsu
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women.

Authors:  Ting-Yuan David Cheng; Xiaoling Song; Shirley A A Beresford; Gloria Y F Ho; Karen C Johnson; Mridul Datta; Rowan T Chlebowski; Jean Wactawski-Wende; Lihong Qi; Marian L Neuhouser
Journal:  Cancer Causes Control       Date:  2017-09-12       Impact factor: 2.506

9.  A new biological rhythm mutant of Drosophila melanogaster that identifies a gene with an essential embryonic function.

Authors:  L M Newby; F R Jackson
Journal:  Genetics       Date:  1993-12       Impact factor: 4.562

10.  1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.

Authors:  C M Hansen; T L Frandsen; N Brünner; L Binderup
Journal:  Clin Exp Metastasis       Date:  1994-05       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.